Amlodipine in the current management of hypertension

Journal of Clinical Hypertension, Journal Year: 2023, Volume and Issue: 25(9), P. 801 - 807

Published: Aug. 7, 2023

Hypertension is the leading cause of death worldwide, affecting 1.4 billion people. Treatment options include widely used calcium channel blockers, among which amlodipine, a dihydropyridine, has unique characteristics that distinguish it from other drugs within this class. This review aims to provide an updated overview evidence supporting use amlodipine over past 30 years and highlights its cardiovascular benefits in current hypertension management. Amlodipine low renal clearance (7 mL/min/mg) long half-life (35-50 h) duration action, allows sustain anti-hypertensive effect for more than 24 h following single dose. Additionally, blood pressure (BP) control maintained even when dose been missed, providing continuous protection case incidental noncompliance. It proven reduce BP variability successfully lower BP. also controls patients with systolic/diastolic 130/80 mm Hg or higher, diabetes, chronic kidney disease without worsening glycemic function. wise choice older adults due ability protect against stroke myocardial infarction. Side effects edema, palpitations, dizziness, flushing, are common higher 10 mg. cost effective predicted be saving compared usual care.

Language: Английский

---

Pharmacogenetics and the Practice of Medicine

International Journal of Advanced Research in Science Communication and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 549 - 557

Published: Jan. 10, 2025

Drug–Drug-Interactions (DDI) are a well-known cause of adverse drug events 1.The number potential interactions increases exponentially with the ofTaken drugs, making it hard to consider all in polypharmacy patients.Drug interaction databases can help clinician recognize and avoid drugInteractions.2 A phenomenon be observed dailypractice, though: even if Database warns about clinicallyrelevant DDI, patient may not show any signs aGiven DDI. This discrepancy between scientific evidence clinical reality causes alertFatigue also raises conflicts DDI warning pharmacists no Drug event-observing physicians.

Language: Английский

---

Hypertension and arterial wall stiffness in clinical practice: literature review

Russian Journal of Cardiology, Journal Year: 2024, Volume and Issue: 29(5), P. 5924 - 5924

Published: April 26, 2024

Arterial stiffness, as a marker of subclinical target organ damage in patients with hypertension (HTN), is an important and independent predictor mortality cardiovascular morbidity. The review examines factors contributing to increased vascular wall stiffness focus on smoking, pathogenesis arterial aging, the effect systolic pulse pressure. Particular attention paid pressure risk events, primarily incidence stroke cognitive impairment. Thiazide-like diuretics calcium antagonists have greatest evidence base HTN treatment elderly due their ability reduce pressure, positive prognosis. use amlodipine/indapamide retard combination promotes more effective HTN.

Language: Английский

---

Safety of combined drug use in patients with cardiovascular and cerebrovascular diseases: an analysis based on the spontaneous reporting database of adverse drug reactions in Hubei Province

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 8, 2025

There is a lack of studies investigating the safety combination regimens specifically for cardiovascular and cerebrovascular diseases. This study aimed to evaluate drugs diseases using real-world data. We analyzed adverse drug reaction data received by Hubei Adverse Drug Reaction Center from first quarter 2014 fourth 2022. The combined in different people was assessed association rule method Ω shrinkage measurement. A total 53,038 reports were included this study, revealing 9 signals reactions caused drugs. strongest signal found jaundice amlodipine atorvastatin (Ω 0.025:3.08, lift: 1116.69, conviction: 1.75). Additionally, aspirin with other associated hemorrhaging various organs. Female patients showed cold when taking vitamin C B6 together compared male 0.025:0.89, 7.15, 1.12). Patients under 60 years old had palpitations combining eritrea bei sha Tanzania felodipine 0.025:0.41, 14.65, 3.8), an erythema nifedipine 0.025:0.23, 8.17, 1.077). Among identified 4 off-label that require further clinical research exploration confirmation, order provide more scientifically informed labeling. Five events aspirin-induced bleeding identified. Notably, observed populations, suggesting need future expedite development personalized medicine.

Language: Английский

---

Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled by Amlodipine: A Phase III, Multicenter, Double‐Blind, Parallel‐Group, Randomized Controlled Trial

Journal of Clinical Hypertension, Journal Year: 2025, Volume and Issue: 27(1)

Published: Jan. 1, 2025

This study aimed to assess the efficacy and safety of a combination therapy Allisartan Isoproxil 240 mg Amlodipine 5 (ALI/AML) compared AML monotherapy in patients with mild-to-moderate essential hypertension. In this phase III, multicenter, double-blind, parallel-group, randomized controlled trial, aged 18-70 years mean sitting systolic blood pressure (msSBP) between 140 <180 mmHg diastolic (msDBP) 90 <110 mmHg, following 4-week treatment mg, were 1:1 receive either ALI/AML or once daily for 12 weeks. 12-week double-blind period was followed by an open-label extension through week 52. A total 300 enrolled, 149 151 randomly assigned groups, respectively. Of these, 257 completed study. Baseline demographics characteristics comparable groups. After weeks, reduction msSBP (the primary endpoint) significantly greater group (-15.7 vs. -10.2 p = 0.0019). Similarly, reductions msDBP (-5.7 -2.4 < 0.001) 24-h ambulatory SBP DBP (-10.4 -7.7 -5.6 -3.8 mmHg) more pronounced group. Additionally, higher proportion achieved both BP response target office (51.4% 37.4%, 42.5% 30.6%, 0.05). The generally well tolerated, antihypertensive effect maintained up 52 hypertension inadequately AML, provided superior effective than monotherapy. once-daily single-pill demonstrated promising tolerability. Trial Registration: ClinicalTrials.gov identifier: NCT06465264.

Language: Английский

---

Management of perianesthesia in benign prostate hyperplasia patients with transvesica prostatectomy and uncontrolled hypertension: A case report

BIO Web of Conferences, Journal Year: 2025, Volume and Issue: 152, P. 01009 - 01009

Published: Jan. 1, 2025

The prevalence of Benign Prostate Hyperplasia (BPH) increases at the age 40 years to 90 years. Anaesthesia in elderly patients with comorbidities can be difficult for anaesthesiologist. minimum dose option is used minimize occurrence myocardial depression and other complications. In this paper, we describe management anaesthesia Transvesica Prostatectomy (TVP) surgery BPH accompanied by uncontrolled hypertension. method research a case study data collection techniques through observation, interviews, looking results examining related data. subjeck was male patient diagnosis who underwent TVP. result conclusion refer collaborative use Subarachnoid Block (SAB) or spinal anesthesia induction drugs (Bupivacaine Fentanyl) consideration due patient’s advanced minimizing morbidity mortality. intervention given regarding health problems which carried out providing nursing care during perioperative phase showed good without complications that disrupted future life

Language: Английский

---

UHPLC-MS/MS method for the simultaneous quantification of five calcium channel antagonists’ drugs in human plasma

Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 184, P. 117873 - 117873

Published: Feb. 5, 2025

Language: Английский

---

“Aprocitentan in hypertension management: clinical efficacy, safety, and future prospects”

Annals of Medicine and Surgery, Journal Year: 2025, Volume and Issue: 87(3), P. 1472 - 1478

Published: Feb. 6, 2025

Language: Английский

---

Amlodipine-Associated Angioedema: An Integrated Pharmacovigilance Assessment Using Disproportionality and Interaction Analysis and Case Reviews

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(4), P. 1097 - 1097

Published: Feb. 8, 2025

Background: Amlodipine has recently been incidentally reported with angioedema and is frequently prescribed renin–angiotensin–aldosterone system inhibitors (RAAS-i) for hypertension management. While RAAS-i drugs are known to cause angioedema, the risk associated amlodipine alone or in combination remains unclear. This study aimed evaluate association between use using pharmacovigilance data. Methods: We analyzed adverse event reports from US FDA Adverse Event Reporting System both frequentist Bayesian approaches. Drug–drug interactions were assessed multiplicative models. Additionally, we conducted a systematic review of published case amlodipine-associated angioedema. Results: Among 29,661,136 reports, 2076 cases identified (1067 alone, 1009 amlodipine–RAAS-i combinations). Significant safety signals detected aliskiren, specific ACE (quinapril, benazepril, trandolapril, fosinopril, perindopril), certain ARBs (candesartan, losartan). No significant observed except amlodipine–trandolapril combination. A demonstrated definite causality two possible others, most patients presenting oropharyngeal/facial edema achieving complete recovery following drug discontinuation standard therapy. Conclusions: Our findings suggest potentially increased amlodipine, as monotherapy combinations. these results should not discourage appropriate clinical use, they emphasize importance monitoring particularly during therapy initiation. The this need be validated prospective studies further elucidation underlying mechanisms.

Language: Английский

---

Looking for approved-medicines to be repositioned as anti-Trypanosoma cruzi agents. Identification of new chemotypes with good individual- or in combination-biological behaviours

Memórias do Instituto Oswaldo Cruz, Journal Year: 2025, Volume and Issue: 120

Published: Jan. 1, 2025

The neglected illness Chagas disease is treated with limited efficacy and adverse effects by old drugs. Due to the low interest of pharmaceutical industry in targeting economically depressed-patients, repurposing a tool that should be applied because it can introduce new anti-Chagas entities into clinic at reduced costs. To investigate repurposing/combination medicines strategies as treatment. Epimastigotes, trypomastigotes amastigotes Trypanosoma cruzi were vitro exposed 28 Uruguayan-approved not previously tested, FDA-approved evaluated, three reference agents. Parasite inhibition was assessed for best drugs, pairs-isobolographic studies, looking synergism/additivity/antagonism, done. Macrophages used study selectivity. For some relevant agents, we analysed whether mammals´ action mechanisms are operative epimastigotes-T. cruzi. From anti-epimastigotes monotherapy-screening, found 18% them showed better/comparable activities than references. Additionally, binary-combinations 8% additive, 4% synergic rest antagonism. Favourably, macrophages-cytotoxicity four antagonists. Naftazone pinaverium bromide, tested against T. cruzi, maintained their activity amastigotes. identified open door designing anti-T. Using approved-medicines good strategy treatments.

Language: Английский

---